On July 22, 2026, a transmission line fault in Ashburn, Virginia—the heart of the world’s largest data center cluster—knocked more than 3 gigawatts of load off the grid in seconds. And it wasn’t the first time. Two years earlier, a single failed surge arrester dropped roughly 60 Virginia facilities and 1,500 megawatts at once. No one could anticipate so much uniform load responding to grid faults the same way, at the same time.

The AI power debate is mostly about generation: more turbines, more solar, more transmission. The grid needs more electrons. But the outages in Virginia weren’t supply failures; they were architecture failures. And a giant wave of interconnections is arriving on that same architecture, putting grid reliability at risk. It’s a problem nobody wants to own.

Asking more from the grid

The grid was built around predictable loads: steel mills, refineries, and houses at dinnertime. Different load sizes, same process—drawing power smoothly, misbehaving occasionally, and recovering gracefully.

But AI data centers don’t behave that way.

An AI campus can swing 70% of its load in milliseconds during a training run, then trip offline just as fast at the first sign of trouble upstream to protect billions in compute. Each is rational alone. Together, at gigawatt scale, they’re a problem the grid has never solved—and the next wave of data center campuses is planned at exactly that scale.

Where the old stack breaks

The standard data center power stack hasn’t changed in decades. Medium-voltage power arrives, transformers step it down, low-voltage uninterruptible power supply (UPS) units condition it, and it reaches the racks. Push that design to AI scale, and it cracks in three places.

First, the UPS sits deep inside the building, close to the racks. But its batteries are an undersized spare tire, designed to handle an outage for a few minutes, not to absorb load swings this fast and volatile around the clock.

Second, the UPS spends most of its life in bypass. Legacy converters waste enough power that operators run in eco-mode: A static switch feeds the racks directly from the grid and nothing filters in either direction. The compute’s swings go out raw, and grid transients—sub-millisecond events that can damage or take down equipment—come in too fast for any switch to catch.

Third, the protection logic was written when “large load” meant 50 megawatts. This protection logic can’t see the grid it is now a part of, so when trouble hits upstream, it does exactly the wrong thing: it drops out. In the 2024 Virginia event, most of the lost load traced to protection schemes that count voltage dips and disconnect on the third one—as designed, at the worst moment.

This isn’t sloppy engineering. It’s careful engineering the load has outgrown.

Moving into the path

The fix is three moves, made together.

Move it up—from 480 volts to medium voltage (13.8 kilovolts and higher), the voltage large sites draw from the grid.

Move it out—from the data hall to modular enclosures near the substation so the building holds only compute and the cooling that keeps it alive.

Move it into the path—instead of a battery that watches and reacts, a system every electron runs through, all the time. There’s nothing to detect and nothing to switch because nothing was ever routed around it.

On paper, three straightforward upgrades. In practice, they rewrite every line item downstream.

Making the change

When thousands of GPUs spin up together, the system absorbs the swing and hands the grid a flat load profile. When a disturbance hits, the equipment behind it never notices. A difficult neighbor becomes a predictable one. And when the utility needs help, it becomes a useful one.

Interconnection changes, too. The utility certifies one medium-voltage box instead of untangling every transformer, UPS, chiller, pump, and switchgear lineup behind it. Engineers swap chip generations without a fresh interconnection study. Months come off the permitting timeline.

Inside the fence, UPS rooms become compute or cooling space. Density per construction dollar climbs.

And the economics flip. Equipment that runs at medium voltage, sits outside, and stores its own energy can qualify for tax credits, and earn revenue in grid programs like peak shaving and demand response. Backup power stops being insurance and starts paying for itself.

The architecture test

In early 2026, we tested a full-scale system at the National Laboratory of the Rockies, a U.S. Department of Energy facility and the only place in the Western Hemisphere that can replicate real grid faults and AI-scale load swings concurrently in the same loop.

We hit it from both directions: real AI load profiles hit the compute side at full medium voltage. Grid faults hit the utility side, including a full zero-voltage event. The compute side didn’t flinch. Neither did the grid side. It cleared the large-load voltage ride-through requirements from the Electric Reliability Council of Texas (ERCOT), the grid operator, with room to spare.

Those rules exist because operators no longer take facilities this size on faith, and more are coming. Most of the industry treats them as hurdles. A medium-voltage, inline system clears them out of the box. Compliance isn’t an added feature. It’s what the architecture does.

The new layer

Much of what looks like a grid problem in the AI buildout sits inside the fence, in equipment sized for a load that no longer exists. Move the right pieces up, out, and into the path, and a grid liability becomes a grid asset. Density goes up. Permitting time comes down. Backup power earns its keep.

The engineering works—and the next wave of AI factories is being built on it. The industry hasn’t named this layer yet. We call it the medium-voltage AI UPS. The name matters less than the choice: those factories can arrive as a strain on the grid or as strength for it. We already know how to build the second kind.    

This content was produced by ON.energy. It was not written by MIT Technology Review’s editorial staff.

The entrance of major AI companies into healthcare is a meaningful and welcome development, accelerating the technical foundation available to the industry.

Their models are increasingly capable of processing long clinical records, interpreting complex terminology, comparing documentation against evidence and generating coherent summaries from large volumes of information. For clinicians, operators, and administrative teams who spend significant time searching through fragmented data, these advances are helping reduce cognitive burden and make high-value information easier to access.

But healthcare leaders should not confuse model capability with operational capability.

Healthcare’s administrative challenges are caused by fragmented information, fragmented workflows, and fragmented accountability, not a lack of information. The industry has spent decades investing in systems that capture activity: electronic health records, billing platforms, payer portals, scheduling systems, call center platforms, and analytics applications. Each system records something important. But few were designed to reason across the full chain of decisions that determines whether patients get timely access, clinicians have the right documentation and providers are reimbursed appropriately.

This is the problem that AI must now confront.

Revenue cycle is becoming one of healthcare AI’s proving grounds

The revenue cycle is the process healthcare providers use to get paid for care — from scheduling and registration through coding, billing, payer follow-up, and payment collection.

It is unusually suited to rigorous AI deployment because it combines high transaction volume, complex reasoning, structured and unstructured data, measurable outcomes, and significant operational variation. It also sits at the intersection of financial performance, patient access, and administrative workload.

A single claim can be influenced by patient insurance information, clinical documentation, coding rules, payer-specific policies, prior authorization requirements, medical necessity criteria, and many other data sources and operational processes. A breakdown in any one of those areas can create downstream consequences weeks or months later.

This is why generic automation has often fallen short.

Traditional robotic process automation works well when workflows are stable and rules are predictable, but healthcare administration is neither. Payer requirements change. Documentation expectations evolve. Exceptions are common and often material.

Large language models improve part of the equation, extracting meaning from narrative text, summarizing records and supporting reasoning over complex documentation. But when used alone, they inherit important limitations. They may produce plausible outputs without sufficient traceability. They may lack awareness of local workflow constraints. They may miss payer-specific history or context that determines whether an action is likely to change an outcome.

Why foundation models will become necessary but insufficient

The major AI firms are solving real technical problems for healthcare.

Better context windows make it easier to process longitudinal records. Stronger reasoning improves the interpretation of complex clinical scenarios. Better multimodal capabilities may eventually help connect text, imaging, structured data, and clinical signals in more useful ways. Safer model behavior and healthcare-specific tuning will continue to improve adoption.

These capabilities will make healthcare work faster, more consistent and easier to navigate. But they will not, on their own, solve deep-rooted administrative complexity.

Much of healthcare’s operational knowledge does not live in general medical literature, coding manuals, or public payer guidance. It lives in the accumulated experience of what actually happens after decisions are made. For example:

• Why does one appeal strategy outperform another?
• Which documentation gaps are most likely to cause reimbursement delay?
• How does a specific payer respond to a particular clinical argument?

These insights are behavioral, operational, and longitudinal. They emerge from years of transactions, outcomes, exceptions, and human judgment.

As foundation models become more capable, access to baseline healthcare knowledge will become less differentiating. Most leading systems will be able to interpret ICD-10 codes, recognize medical terminology, summarize payer policies, and reason over public clinical criteria. The durable advantage will come from how organizations combine that model intelligence with proprietary operational data, structured knowledge, workflow context, and governance.

The technical shift: From automation to orchestration

Agentic orchestration turns foundation model understanding into coordinated action — intelligence that can follow work across systems, apply the right rules, adapt when something changes, and keep learning from what happens next.

A prior authorization workflow, for example, may require retrieving clinical documentation through fast healthcare interoperability resources (FHIR) APIs, mapping patient history to payer criteria, identifying missing evidence, generating a submission packet, routing exceptions to a specialist, monitoring payer response, adjusting patient care pathways, and learning from the outcome.

This type of workflow requires coordination. It also requires guardrails: regulatory requirements, privacy standards, clinical policies, coding rules, payer criteria, and organizational risk thresholds. One promising approach is hybrid architecture that combines LLMs with structured knowledge bases, symbolic logic, reinforcement learning, and deterministic validation layers.

At Ensemble, this is the design principle behind EIQ, our revenue cycle intelligence engine. EIQ brings together operational activity, clinical documentation, payer behavior, and reimbursement outcomes into a continuously learning intelligence layer that’s integrated with the hospital’s electronic health record (EHR). It supplements the system of record with a system of intelligence, designed to connect information and surface actions most likely to improve outcomes.

EIQ uses a neuro-symbolic approach that combines LLMs and custom small language models with rules-based reasoning. That architecture is built on one of the most robust datasets in healthcare, informed by more than a decade of award-winning operational performance, transaction history, payer behavior, and operator decision-making. The language models help interpret information and generate human-readable outputs. The symbolic layer represents policies, rules, payer requirements, and workflow constraints so the system can apply guardrails, make reasoning steps more traceable and recommend actions that fit the specific operational context.

What the next decade will reward

The contribution of major AI firms to healthcare will be significant. Their models will become faster, safer, more capable, and more accessible.

But the next decade of healthcare AI will be defined by integration, not model capability alone.

The organizations that create the most value will be those that connect models to governed data, operational workflows, domain expertise, human oversight, and measurable outcomes. They will understand that healthcare intelligence cannot live in a separate interface. It has to exist inside the decisions that shape access, documentation reimbursement, and patient experience.

This content was produced by Ensemble. It was not written by MIT Technology Review’s editorial staff.

Inside Electronics explores SWAP-C tradeoffs, software-defined radios, and the future of connected UAV systems.

Plug a phone into a modern charger and the first 10 minutes are impressive. The next 20 are not.

This is not a defect. It’s the connected device protecting itself. As temperature rises during charging, a smartphone’s battery management system reduces the current it will accept, because heat accelerates the chemical degradation that permanently reduces battery capacity. The charger may be capable of delivering more, but the device simply stops taking it.

For anyone building products in the portable power category, this creates an uncomfortable gap between specification and experience. A device rated at 25 watts is accurate in the sense that it can deliver 25 watts. Whether it delivers 25 watts for the duration of a charge is a different question, and one the specification does not answer.

The specification gap

The gap matters commercially because it is invisible at the point of purchase and obvious in use.

Consumers compare wattage figures on packaging. They don’t compare thermal curves, because thermal curves are not published publicly. The result is a category where products differentiate on a number that describes peak output rather than sustained output, and where the actual user experience of two products with identical specifications can diverge substantially.

This is particularly acute in magnetic wireless charging. Inductive power transfer generates heat at both the transmitting and receiving coils, and the magnetic attachment that makes these products convenient also places the heat source in direct contact with the device it is charging. Convenience and thermal performance are working against each other by design.

The industry’s response for the past several years has been materials science. Graphite sheets, thermal interface materials, conductive housings, and heat-spreading layers have all improved how efficiently accumulated heat moves away from the source. Each generation has been incrementally better than the last.

But passive dissipation has a structural limitation: it can only move heat that has already been generated, and only as fast as the surrounding air will accept it. In a sealed, pocket-sized enclosure, that ceiling arrives quickly. Improving the materials slows the rate of temperature rise. It does not prevent the temperature rise.

Moving from dissipation to removal

The alternative is active thermal management, which is standard in stationary electronics and largely absent from portable ones for reasons that are easy to understand. Fans add volume, weight, moving parts, and noise. In a product category defined by portability, each of those is a meaningful cost.

At Anker, which manufactures charging and power products, engineering teams spent the past several development cycles working on whether that tradeoff could be made acceptable rather than eliminated. The approach involves several interacting systems: a micro centrifugal fan, dual airflow channels routed to avoid interference with the magnetic array, a three-layer graphene heat-spreading layer, and a control algorithm that modulates fan speed based on real-time temperature and battery state rather than running at a fixed rate. The result is that the Anker MagGo Power Bank 2 Pro has become the world’s fastest and coolest wireless power bank.

In internal testing, at 77 °F (25 °C) ambient, the back of the power bank stays below 96.8 °F (36 °C) throughout wireless charging, 21.6 °F (12 °C) below the international standard limit of 118.4 °F (48 °C), for a comfortable grip. Comparable magnetic power banks in the same testing typically reached 113 °F (45 °C) or higher within 20 minutes. The functional consequence is that the connected device does not reach the threshold at which it begins reducing charge acceptance, so 25 watts of Qi2.2 magnetic wireless charging is delivered as a working rate rather than an opening rate. In practice, an iPhone 17 Pro reaches 50% charge in 25 minutes. The Anker MagGo Power Bank 2 Pro’s premium performance in both charging speed and thermal management is certified by SGS, an independent testing and certification company.

The same principle applies in reverse. Recharging a power bank generates heat too, which is why devices in this category are often slow to recharge, leaving users with an empty accessory at the moment they need it. Active cooling during input allows the unit to accept 45 watts and reach 80% in 52 minutes.

What this suggests about the category

There is a broader pattern here worth naming, because it is not unique to charging.

When a category improves along a single axis for long enough, the constraint usually migrates somewhere else. Charging spent a decade optimizing power delivery. Power delivery is now, for most practical purposes, solved: the electronics can supply more energy than the receiving device is willing to accept. The binding constraint moved to thermal management, and the industry continued optimizing the axis it had always optimized, because that is the axis the specifications describe.

Recognizing when a constraint has moved is difficult precisely because the old metric keeps improving. Wattage figures have continued to climb. Products have continued to get faster on paper. The measurement stayed valid while quietly ceasing to describe the thing users experience.

For product organizations, the practical question is whether their specifications still measure the constraint or merely measure the capability. The two align until the constraint shifts and specifications rarely shift with it.

The transparency problem

A second implication follows from the first. If sustained performance differs meaningfully from peak performance, and if only peak performance is disclosed, then buyers cannot evaluate the products in front of them.

This is one reason Anker is adding displays on charging products. The Anker MagGo Power Bank 2 Pro shows real-time power, temperature, battery level, and estimated time remaining. Some of that is user convenience. But some of it is a Anker stating a deliberate position—this category deserves to have the complete and accurate data made transparent to all.

Anker expects independent reviewers to test these claims and considers our internal numbers to be the correct outcome. The gap between specification and experience closes faster when the experience is measurable. The Anker MagGo Power Bank 2 Pro will be available in the U.S. on September 17, 2026.

This content was produced by Anker. It was not written by MIT Technology Review’s editorial staff.

Check out this QuickChat to learn how developments are reshaping RF design and test workflows, reducing engineering effort, and helping teams accelerate product development.

I have spent much of my career looking at the defense industrial base from different vantage points: as a warfighter, inside major defense companies, and now leading a company whose […]

The post Speed to Field Starts Below the Prime appeared first on SpaceNews.

For most of its history, the United States has been largely insulated from foreign threats. Vast oceans made it an impractical destination for invading armies before the advent of modern […]

The post Why Golden Dome Demands a Reimagined and Revitalized Industrial Base appeared first on SpaceNews.

Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to treat conditions across most major acute and chronic diseases), the complexity is even greater.

Scientists explore vast quantities of possible molecules, looking for the rare few that will bind to the right target, remain stable in the human body, and be manufacturable at scale. Today, AI is speeding up these processes and has quickly become a core part of the infrastructure in pharmaceutical R&D.

AI-assisted design is a growing part of how biologic drug candidates are developed, and companies like AstraZeneca are actively building its engineering teams to push this further. “Everything we do, whether it’s design, make, test, or analyze, is now computationally enhanced,” says Puja Sapra, senior vice president and head of R&D biologics engineering and oncology targeted discovery at AstraZeneca. “The cycle times are getting shorter while productivity and innovation increase.”

Sapra explains that AstraZeneca’s approach follows a build-measure-learn loop. AI generates or prioritizes candidate molecules computationally, predicting which designs are most likely to succeed. Scientists then focus lab resources only on the top-ranked candidates. This leads to a tighter feedback cycle with fewer dead ends, faster iteration, and the ability to go after disease targets that were previously considered untreatable by medicine. Because the number of possible molecular combinations far exceeds what any human team can systematically explore, using AI to narrow and refine the options for testing has become a major focus in biologics drug design.

Navigating complex drug design problems

Beyond accelerating timelines, AI is also being applied to the discovery of entirely new classes of medicines. Traditional biologics typically target one disease pathway. The next generation of drugs can hit multiple targets simultaneously or precisely deliver therapeutic payloads to specific cells. Achieving this requires optimization across many variables at once. Looking ahead AI-driven models could help design these increasingly complex, multi-specific biologics, explains Puja Sapra. “For example,” she continues, “such models could help identify which two or three targets to prioritize based on the underlying biology, then optimize across multiple parameters to balance a molecule’s potency, stability, manufacturability, and safety.” “Drugging the undruggable is becoming a reality,” Sapra says. “These technologies will eventually enable us to develop medicines against targets once thought impossible to reach. The potential for benefit to patients is remarkable.”

The data moat

McKinsey estimates that generative AI, combined with other computational tools, could cut drug discovery timelines by as much as 50%. But every AI model is only as good as its training data. In drug discovery, that means ample quantities of high-quality biological data. Experiments can provide a rich source of such data. Whether they succeed or fail, each experiment generates a signal about what does and does not work.

“Data is our differentiator,” says Sapra, explaining how the company’s datasets are proprietary and multimodal and include molecular structures, binding measurements, safety profiles, and manufacturing outcomes. “We’ve built an intentionally diverse portfolio across multiple disease areas and drug types. All of that data empowers us to fine-tune frontier AI models with richer, more representative training sets.” She continues, “Further, we have invested in deep screening technologies to generate additional datasets required in volume to constantly refine and validate our models.”

Building an autonomous discovery engine

To bring all of that data together in one place, AstraZeneca is building what it calls a “lab of the future” facility in Kendall Square, Cambridge, Massachusetts where AI and robotic automation will be able to form a continuous, closed-loop discovery system. “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data,” explains Sapra. That data feeds directly back into the models, accelerating each subsequent cycle.

“Throughout, scientists will remain central to the process, providing the oversight, judgement, and strategic direction that ensure outputs are explainable, tolerable, and directed toward potential patient benefit,” she adds.

Eventually, automated high-throughput systems will be able to make and evaluate thousands of molecular interactions on a weekly basis. “This will generate AI-ready data at a scale that traditional workflows cannot match,” Sapra says. “Robotic sample handling, automated quality checks, and integrated data pipelines also have the potential to help accelerate early drug development timelines significantly.”

The next frontier: Generating medicines from scratch

Ultimately, Sapra says, the end-state vision for AI in biologic drug discovery is what the field calls “de novo” design. For this, the goal is for AI to generate entirely new protein sequences that precisely fit the desired drug properties. This includes designing the structure, predicting safety, how it will behave in the body and how to make it manufacturable.

“The field is making great progress toward a completely AI-generated biologic, designed from scratch all the way to a clinical candidate,” Sapra says. “As we continue to leverage frontier models and fine-tune them with the right datasets, we bring ourselves closer to this reality. I believe it will come. It’s a matter of time.”

Several key elements are needed to reach this point, however. First is richer and more standardized training data across the industry. Second, robust evaluation benchmarks for AI-generated candidates. And third, teams that know how to work at the intersection of machine learning and biology. Of all the prerequisites, however, safety prediction may be the most consequential, and perhaps the least discussed, Sapra says.

“One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body,” Sapra explains. AstraZeneca is tackling this with what amounts to virtual clinical trials. These are advanced cell systems and micro-scale organ models that function as physical testbeds, paired with AI that learns from their outputs.

 “These systems have the potential to generate enhanced biological signals without traditional testing bottlenecks, and they’re a critical missing piece in closing the loop between AI-generated designs and clinical-ready candidates,” Sapra adds.

A shift currently underway is the move toward agentic AI systems that can simultaneously generate molecule candidates and predict how efficacious and safe they are likely to be. These autonomous workflows can connect disease-level insights directly to molecule design, bridging what were previously separate data silos. “The complexity of the biology goes hand-in-hand with the design of the molecule,” summarizes Sapra.

Human talent unlocks AI potential

The transformation underway in biologics is not just about technology. “With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients,” says Sapra.

For scientists, working with AI is a collaborative process. “Scientists will work hand-in-hand with these model systems,” she says. “There will be a world where models will design molecules, then scientists will work with the systems to test those molecules and put all that data together.” Through this process of human checks, balances, and judgement calls, the models will evolve and constantly improve, ultimately with potential to benefit patients.

For engineers, designing and building effective systems ready for human-AI collaboration will mean ensuring high levels of model transparency and explainability. According to Sapra, AstraZeneca’s engineering teams include data scientists, automation specialists, and AI engineers, who are developing systems that act as “thinking partners” rather than black boxes. “Engineers are designing systems that generate, validate, and learn at speed. And the problems are genuinely hard: Multimodal data fusion, closed-loop optimization, uncertainty quantification, and interpretability at the point of clinical decision-making,” she adds.

In taking on such technically demanding challenges, engineers and scientists have the opportunity to contribute to the research and development of potentially life-changing treatments for many diseases, says Sapra. “The biologic medicines we can develop today, and those we’ll design tomorrow, depend on combining world-class AI and engineering talent with deep scientific expertise.”

This article has been initiated and funded by AstraZeneca.  Z4-85058, July 2026.

This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff. It was researched, designed, and written by human writers, editors, analysts, and illustrators. This includes the writing of surveys and collection of data for surveys. AI tools that may have been used were limited to secondary production processes that passed thorough human review.

The conversation about AI often centers on algorithms, computing power, or huge investments in new semiconductor fabrication plants and hyperscale data centers. But beneath each of these advances is another layer of innovation that makes them possible: advanced materials.

Every new generation of AI technology demands more processing power, more memory, greater energy efficiency, and higher reliability. Every increase in computing performance increases the physical demands placed on the systems that make and run AI.

Delivering these gains depends not only on advances in chip design and system architecture, but on advances in the materials that enable them to perform under extreme conditions.

As AI continues to push the physical limits of semiconductors and data center infrastructure, advanced materials are no longer simply supporting innovation in this area; they are defining the limits of what is possible.

Performance first

Advanced materials exist to solve performance challenges. As AI raises the bar, these challenges are becoming more demanding.

Manufacturing a semiconductor chip today requires thousands of tightly controlled process steps, with almost no room for error. Tiny variations in temperature or chemical instability can create defects that reduce yield and drive up manufacturing costs. With every new generation of semiconductor chips, manufacturers seek advanced materials that can deliver greater purity, higher chemical and plasma resistance, and better stability under increasingly harsh operating conditions.

These are familiar engineering challenges being pushed to new extremes. And it’s here that materials innovation makes the difference with continuous advances in polymers, elastomers, specialty fluids, and other advanced materials that make each new generation of technology possible.

For materials companies, it’s not about reinventing semiconductor manufacturing but about ensuring the materials supporting the industry continue to evolve alongside it. This same principle applies beyond the semiconductor fabrication floor. As AI workloads become more demanding, the physical infrastructure that powers them is evolving rapidly.

Increasing computing density is transforming data center design, driving the need for more sophisticated thermal management, higher-voltage power architectures, increased data storage, and faster, more reliable data transmission. Every part of the system is under greater pressure, from cooling and power management to critical electronic components, such as connectors, capacitors, and hard disk drives.

At Syensqo, we’re building on our expertise in electronic and electrical components, along with insights from other markets, to meet these emerging needs.

For example, as data centers shift to higher-voltage architectures and greater power density, many of the materials challenges we face closely mirror those of electric vehicles. Fluid-circulation know-how from semiconductor and automotive coolant systems, for instance, can be adapted to direct liquid-cooling designs for AI servers. By transferring knowledge across markets, we can accelerate new power and thermal management solutions while supporting the reliability required by next-generation AI infrastructure.

Whether we’re talking about semiconductor fabrication or hyperscale server farms, the challenge for materials science companies is the same: enabling greater performance without compromising reliability.

A new definition of what performance means

While performance remains the first priority, the way performance is defined is changing.

In addition to meeting the increasingly demanding technical requirements of next-generation semiconductors and data centers, there is now an expectation that these materials are developed and manufactured more responsibly.

Perfluoroelastomers, for example, are used to seal semiconductor manufacturing equipment. These materials operate under extreme temperatures, aggressive plasma, and highly reactive chemicals.

To make the process more sustainable, at Syensqo, our next generation of perfluoroelastomers use a fluorosurfactant-free manufacturing process. Our goal was to make a better-performing material, produced in a better way, ensuring manufacturers no longer have to choose between higher performance and a more responsible way of producing the materials that enable it.

This approach reflects a broader reality across the industry.

New materials aren’t adopted simply because they are new. Qualification can take years, and manufacturers only make changes when a material solves a genuine engineering challenge or enables new technology.

Performance remains the price of entry. The difference today is that the definition of performance has expanded. Success increasingly depends on delivering technical excellence through more responsible manufacturing from the outset.

Accelerating the pace of discovery

As the performance bar rises, the way we innovate must evolve with it.

Developing advanced materials has traditionally involved a lengthy process of hypothesis, synthesis, testing, and iteration. While this process remains unchanged, new digital tools are helping researchers move through these cycles faster. By helping researchers identify the most promising candidates earlier, AI can reduce the number of physical experiments required and accelerate the earliest stages of materials discovery.

AI isn’t replacing scientific expertise. It’s helping scientists apply that expertise more effectively, allowing them to spend less time searching for answers and more time solving the industry’s toughest challenges.

At Syensqo, we’re putting this approach into practice through use of several AI tools, including the Microsoft Discovery platform, which are helping researchers identify and evaluate promising molecular candidates for next-generation heat transfer fluids, used in semiconductor manufacturing and data centers.

AI helps our researchers rapidly identify and evaluate promising molecular candidates based on the properties they need to achieve. This allows us to focus laboratory work where it has the greatest potential to deliver results, accelerating discovery and reducing the time needed to turn promising materials into solutions customers can qualify and deploy.

The journey from laboratory discovery to a qualified material will always require scientific expertise, rigorous testing, and close collaboration with customers. But by accelerating the earliest stages of discovery, AI can help materials innovation keep pace with the evolving needs of industries such as semiconductors, electronics, and data centers.

Progress is earned

The future of artificial intelligence will depend on better algorithms, more powerful chips, and larger computing infrastructure. But sustaining that progress will also require advances in the materials that make those technologies possible.

Whether in semiconductor manufacturing or AI infrastructure, progress is earned. Every new generation of technologies raises the bar, and every new material must prove it can deliver the performance, reliability, and efficiency needed before it earns its place.

For materials companies, that remains both the challenge and the opportunity.

This content was produced by Syensqo. It was not written by MIT Technology Review’s editorial staff.

Enterprise computer vision is moving from isolated pilots to production systems that support manufacturing, retail, safety, and operational use cases. In this eSpeaks episode, Dell Technologies’ Jason Nassar explains how vision language models, edge computing, accelerated infrastructure, Dell AI Factory with NVIDIA, Dell Automation Platform, and Dell Distributed Private Cloud are changing what it takes to deploy visual AI at scale.

Scaling AI takes more than adding GPUs. Enterprises need servers, storage, networking, data access, and orchestration to work together so production workloads can grow without exposing costly bottlenecks.

Knowledge assistants can deliver real value when they are grounded in trusted enterprise data. Production success depends on retrieval quality, source traceability, access controls, workflow integration, and ongoing governance.

Agentic AI is pushing workplace AI from assistance into action. To scale safely, enterprises need secure runtimes, governed data access, open ecosystems, and infrastructure built for production AI agents.

By Marc Berte, Founder and CEO of Overview Energy AI is making energy valuable enough that we’re reconsidering where infrastructure should live. Space is increasingly where that conversation leads. Orbital […]

The post What’s the Best Way to Monetize Space Energy? appeared first on SpaceNews.

Across Europe, border environments are becoming increasingly dynamic and complex. Activity can shift within hours—vehicles reposition, staging areas disperse, small watercraft alter routes, and nodes of activity appear and disappear […]

The post Speed as a Strategic Advantage in Border Monitoring appeared first on SpaceNews.

Sponsored by DigiKey and Würth Elektronik, this episode of Inside Electronics focuses on flyback power electronics and how they are applied across different power-supply designs

Sponsored by DigiKey and RECOM Power, this episode of Inside Electronics focuses on next-generation power solutions.